Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Mohs Surgery Gains Popularity Among Older Patients

By HospiMedica International staff writers
Posted on 02 May 2012
Mohs micrographic surgery (MMS) for the treatment of nonmelanoma skin cancer (NMSC) has doubled in the past decade, particularly among patients in their 60’s.

Researchers at the Albert Einstein College of Medicine (New York, NY, USA), the Yale Comprehensive Cancer Center (New Haven, CT, USA), and other institutions conducted a retrospective analysis of Medicare beneficiaries to identify Medicare use rates of MMS and surgical excision for the treatment of NMSC from January 1, 2001, through December 31, 2006. More...
The main outcome measures were surgical treatment, patient, and lesion characteristics associated with treatment type.

The results showed that a total of 26,931 operations were performed for the treatment of NMSC during the study period, of which 36.4% were MMS. Although the rate of surgical excision slightly increased during this period, the rate of MMS doubled. MMS was performed in 46.9% of facial lesions, whereas it was only used to treat 14.7% of total body lesions. The researchers found that age, race, lesion location, and area of country for patient treatment were significantly associated with MMS use; 40.6% of patients aged 67 to 69 underwent Mohs surgery, while among those 85 and older, the percentage was only 33.5%.

Atlanta (GA, USA) had the highest proportion of patients treated with MMS (45.1%); the state of Louisiana had the lowest (11%). High rates were also seen in Detroit (MI), Los Angeles (CA), Iowa, and New Jersey. Among the possible reasons for geographic variation cited by the researchers were sun exposure, higher proportions of elderly in the population, and the presence of academic medical centers with specialized facilities. The study was published in the April 2012 issue of Archives of Dermatology.

“We hypothesize that younger patients and their physicians may be more concerned with cosmetic outcome, tissue preservation, and minimizing recurrence compared with older individuals, who may have comorbidities or other medical needs in which Mohs micrographic surgery would not be an appropriate treatment option,” concluded Cary Gross, MD, of Yale, and colleagues.

MMS is a surgical technique for the removal of skin carcinomas that allows precise microscopic marginal control by using horizontal frozen sections. For example, MMS has become the treatment of choice for basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) at high risk for local recurrence. The advantages of the technique include superior cure rates, maximal tissue conservation, ability to trace perineural or infiltrating tumors histologically, low cost relative to that of radiation therapy, excision, or surgery, and negligible risk of complications from general anesthesia.

Related Links:
Albert Einstein College of Medicine
Yale Comprehensive Cancer Center



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.